Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.00%||71.77||1.0%||$472.12m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.00%||615.24||2.7%||$388.21m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.00%||234.06||1.9%||$331.63m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.00%||3.17||0.7%||$221.59m|
|EXAS||EXACT Sciences Corp.||0.00%||78.43||17.9%||$151.61m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.00%||148.50||8.2%||$151.18m|
|ARNA||Arena Pharmaceuticals, Inc.||0.00%||92.65||13.7%||$144.29m|
|BBIO||BridgeBio Pharma, Inc.||0.00%||12.75||0.0%||$115.66m|
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.